Oral valganciclovir as pre-emptive therapy for cytomegalovirus infection in allogeneic stem cell transplantation recipients

被引：0
|
作者：
Pastore, D. [1 ]
Carluccio, P. [1 ]
Gaudio, F. [1 ]
Perrone, T. [1 ]
Delia, M. [1 ]
Albano, F. [1 ]
Manduzio, P. [1 ]
Fesce, V. [1 ]
Mongelli, P. [1 ]
Liso, V. [1 ]
Specchia, G. [1 ]
机构：
[1] Univ Bari, Bari, Italy
来源：
BONE MARROW TRANSPLANTATION | 2008年 / 41卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
引用
收藏
页码：S266 / S267
页数：2
相关论文
共 50 条
  • [1] Oral valganciclovir as pre-emptive therapy for cytomegalovirus infection in allogeneic stem cell transplantation recipients
    Michael, M.
    Kourti, G.
    Bouzani, M.
    Grispou, O.
    Anagnostopoulou, M.
    Baltathakis, I.
    Apostolidis, I.
    Karakasis, D.
    Harhalakis, N.
    Paniara, O.
    Nikiforakis, E.
    BONE MARROW TRANSPLANTATION, 2007, 39 : S285 - S286
  • [2] Valganciclovir as pre-emptive therapy for cytomegalovirus infection in allogeneic haematopoietic stem cell transplant recipients
    Ruiz-Camps, Isabel
    Len, Oscar
    de la Camara, Rafael
    Gurgui, Mercedes
    Martino, Rodrigo
    Jarque, Isidro
    Barrenetxea, Cristina
    Diaz de Heredia, Cristina
    Batlle, Montserrat
    Rovira, Montserrat
    de la Torre, Julian
    Torres, Antonio
    Aguilar, Manuela
    Espigado, Ildefonso
    Martin-Davila, Pilar
    Bou, German
    Borrell, Nuria
    Maria Aguado, Jose
    Pahissa, Albert
    ANTIVIRAL THERAPY, 2011, 16 (07) : 951 - 957
  • [3] Prospective study of oral valganciclovir for pre-emptive therapy of cytomegalovirus after allogeneic stem cell transplantation
    de la Camara, R.
    Vazquez, L.
    Lopez, J.
    Solano, C.
    Serrano, D.
    Garcia Noblejas, A.
    Ribera Santasusana, J. M.
    Ferra, C.
    BONE MARROW TRANSPLANTATION, 2009, 43 : S246 - S247
  • [4] Oral valganciclovir is an effective primary pre-emptive therapy of cytomegalovirus disease in recipients of allogeneic stem cell transplant
    Candoni, A.
    Mestroni, R.
    Simeone, E.
    Cerno, M.
    Fanin, R.
    BONE MARROW TRANSPLANTATION, 2007, 39 : S175 - S176
  • [5] Oral valganciclovir as pre-emptive therapy for CMV infection post allogeneic haematopoietic stem cell transplantation
    Busca, A
    Locatelli, F
    Ceretto, C
    Ghisetti, V
    de Fabritiis, P
    Mirabile, M
    Gentile, G
    Falda, M
    BONE MARROW TRANSPLANTATION, 2006, 37 : S188 - S188
  • [6] Oral valganciclovir as pre-emptive therapy has similar efficacy on cytomegalovirus DNA load reduction as intravenous ganciclovir in allogeneic stem cell transplantation recipients
    P L J van der Heiden
    J S Kalpoe
    R M Barge
    R Willemze
    A C M Kroes
    E F Schippers
    Bone Marrow Transplantation, 2006, 37 : 693 - 698
  • [7] Oral valganciclovir as pre-emptive therapy has similar efficacy on cytomegalovirus DNA load reduction as intravenous ganciclovir in allogeneic stem cell transplantation recipients
    van der Heiden, PLJ
    Kalpoe, JS
    Barge, RM
    Willemze, R
    Kroes, ACM
    Schippers, EF
    BONE MARROW TRANSPLANTATION, 2006, 37 (07) : 693 - 698
  • [8] Pre-emptive therapy with valganciclovir for cytomegalovirus (CMV) infection after allogeneic haematopoietic stem cell transplantation (Allo-HSCT)
    Topcuoglu, P.
    Arslan, O.
    Ozcan, M.
    Ilhan, O.
    Akan, H.
    Uysal, A.
    Gurman, G.
    BONE MARROW TRANSPLANTATION, 2013, 48 : S322 - S323
  • [9] Valganciclovir is safe and effective as pre-emptive therapy for CMV infection in allogeneic hematopoietic stem cell transplantation
    E Ayala
    J Greene
    R Sandin
    J Perkins
    T Field
    C Tate
    K K Fields
    S Goldstein
    Bone Marrow Transplantation, 2006, 37 : 851 - 856
  • [10] Valganciclovir is safe and effective as pre-emptive therapy for CMV infection in allogeneic hematopoietic stem cell transplantation
    Ayala, E
    Greene, J
    Sandin, R
    Perkins, J
    Field, T
    Tate, C
    Fields, KK
    Goldstein, S
    BONE MARROW TRANSPLANTATION, 2006, 37 (09) : 851 - 856
12345